urologytimes

FDA grants fast track designation to pasritamig for mCRPC

Pasritamig targets KLK2 and has FDA fast track designation for mCRPC, enabling accelerated development and review processes. Phase 1 study showed pasritamig was well-tolerated with promising ...
urologytimes

Katy Beckermann, MD, on ciforadenant plus ipilimumab and nivolumab in ccRCC

Beckermann explained that adenosine blockade may be better shown in the durability of response, so data collection in the study remains ongoing. At the 2025 European Society for Medical Oncology ...
urologytimes

Kim Nguyen Chi, MD, on 177Lu-PSMA-617 vs docetaxel in mCRPC

The PR.21 study found no significant difference in rPFS between 177Lu-PSMA-617 and docetaxel in mCRPC patients. 177Lu-PSMA-617 showed a higher PSA response rate compared to docetaxel, with 36% vs 16% ...
urologytimes

FDA grants priority review to sBLA for EV plus pembrolizumab in cisplatin-ineligible MIBC

The FDA granted priority review for enfortumab vedotin-ejfv plus pembrolizumab in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy. The KEYNOTE-905/EV-303 trial ...
urologytimes

Adjuvant durvalumab plus tremelimumab after RCC resection improves DFS

Adjuvant durvalumab plus tremelimumab improved DFS in resected RCC, especially in high-risk patients, with a 43% reduction in recurrence risk. The trial enrolled patients into three arms, with the ...
urologytimes

Pearls & Perspectives, with Amy Pearlman, MD

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...
urologytimes

News Network: Prostate Cancer and Bladder Cancer at ESMO 2025

Chandler Park, MD, MSc, FACP, interviews urologist Neal D. Shore, MD, FACS, on the top updates in prostate cancer and bladder cancer at the 2025 European Society for Medical Oncology Congress. At the ...
urologytimes

Subcutaneous vs Intravenous Administration of Immune Checkpoint Inhibitors

This discussion compares subcutaneous and intravenous immunotherapy delivery, highlighting differences in clinical use, patient convenience, and overall treatment experience. This program examines the ...
urologytimes

Use of IsoPSA to guide long-term management

Panelists discuss how IsoPSA’s long-term predictive performance supports safer follow-up strategies and greater confidence in risk-based management. Panelists discuss how IsoPSA’s predictive ...
urologytimes

Real-world trials highlighting the predictive value of IsoPSA

Panelists discuss how real-world evidence confirms IsoPSA’s predictive value, showing that high scores align with significantly greater long-term cancer risk. Panelists discuss how real-world trial ...
Urology Times

Belzutifan triplet shows promising efficacy in advanced ccRCC

Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response ...
urologytimes

Minimally Invasive Surgical Treatments vs TURP, Laser Enucleation for BPH

An expert discusses how comparing the durability and treatment effects of newer minimally invasive therapies to gold standard transurethral resection of the prostate (TURP) or holmium laser ...